| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10011252 | Journal of the American Academy of Dermatology | 2005 | 9 Pages |
Abstract
Twelve-week efalizumab treatment resulted in significant improvement; extension of therapy to 24 weeks resulted in additional improvement in patients who initially had not achieved PASI-75. There were no significant changes in safety profile during weeks 13-24.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Craig L. MD, Kim A. MD, PhD, Kenneth B. MD, Alan MD, Steven R. MD, Ivor MD, Patricia A. MD, PhD, Peter G. MA, MS, Alice B. MD, PhD, for the Efalizumab Study Group for the Efalizumab Study Group,